- Home
- NNAVW vs GKOS Comparison
NNAVW vs GKOS Comparison
Compare NNAVW & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNAVW
- GKOS
- Stock Information
- Founded
- NNAVW 2007
- GKOS 1998
- Country
- NNAVW United States
- GKOS United States
- Employees
- NNAVW 96
- GKOS N/A
- Industry
- NNAVW Industrial Machinery/Components
- GKOS Medical/Dental Instruments
- Sector
- NNAVW Industrials
- GKOS Health Care
- Exchange
- NNAVW Nasdaq
- GKOS Nasdaq
- Market Cap
- NNAVW N/A
- GKOS 5.1B
- IPO Year
- NNAVW N/A
- GKOS 2015
- Fundamental
- Price
- NNAVW $4.12
- GKOS $89.73
- Analyst Decision
- NNAVW
- GKOS Strong Buy
- Analyst Count
- NNAVW 0
- GKOS 13
- Target Price
- NNAVW N/A
- GKOS $155.00
- AVG Volume (30 Days)
- NNAVW 53.1K
- GKOS 981.4K
- Earning Date
- NNAVW 03-12-2025
- GKOS 04-30-2025
- Dividend Yield
- NNAVW N/A
- GKOS N/A
- EPS Growth
- NNAVW N/A
- GKOS N/A
- EPS
- NNAVW N/A
- GKOS N/A
- Revenue
- NNAVW $4,963,000.00
- GKOS $383,481,000.00
- Revenue This Year
- NNAVW N/A
- GKOS $27.84
- Revenue Next Year
- NNAVW N/A
- GKOS $27.99
- P/E Ratio
- NNAVW N/A
- GKOS N/A
- Revenue Growth
- NNAVW 43.44
- GKOS 21.85
- 52 Week Low
- NNAVW $4.47
- GKOS $77.91
- 52 Week High
- NNAVW $4.70
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- NNAVW N/A
- GKOS 41.74
- Support Level
- NNAVW N/A
- GKOS $87.17
- Resistance Level
- NNAVW N/A
- GKOS $94.55
- Average True Range (ATR)
- NNAVW 0.00
- GKOS 6.28
- MACD
- NNAVW 0.00
- GKOS 1.04
- Stochastic Oscillator
- NNAVW 0.00
- GKOS 52.17
About NNAVW NextNav Inc. Warrant
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.